Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma

Cancer Chemother Pharmacol. 2019 Mar;83(3):439-442. doi: 10.1007/s00280-018-3743-0. Epub 2018 Dec 13.


Purpose: Platinum-based doublet chemotherapy and radiotherapy are the standard treatment option in advanced squamous cell carcinoma patients. However, few agents could be selected for subsequent post-second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, apatinib had been proved in advanced gastric cancer. Here, we showed its efficacy and safety in lung squamous cell carcinoma.

Methods: In this retrospective study, 13 advanced lung squamous cell carcinoma patients were enrolled. They received doublet chemotherapy or docetaxel as the first-line treatment. After disease progressed, all patients were administrated apatinib monotherapy (250-425 mg/day) for second-line or fourth-line therapy.

Results: After apatinib monotherapy, two patients achieved partial response, four patients achieved stable disease, and seven patients achieved progression disease. The medium PFS was 3.1 months. The median OS had not yet been reached. The objective remission rate was 15.4% (2/13). The total disease control rate was 46.2% (6/13). The main advert effects were vomiting and hypertension.

Conclusion: Apatinib might be an option as rescue treatment in advanced lung squamous cell carcinoma.

Keywords: Apatinib; Squamous cell carcinoma; VEGFR-2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Hypertension / chemically induced
  • Hypertension / epidemiology
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects
  • Pyridines / administration & dosage*
  • Pyridines / adverse effects
  • Retrospective Studies
  • Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors
  • Vomiting / chemically induced
  • Vomiting / epidemiology


  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyridines
  • apatinib
  • KDR protein, human
  • Vascular Endothelial Growth Factor Receptor-2